Omega-3 polyunsaturated fatty acid (ω-3 PUFA) therapy continues to show great promise in
primary and, particularly in secondary prevention of cardiovascular (CV) diseases. The most …

Omega-3 polyunsaturated fatty acids (PUFA) reduce fasting and postprandial triglycerides,
decrease platelet and leucocyte reactivity, and may slightly decrease blood pressure …

Opinion statement Early secondary prevention trials of fish and omega-3 polyunsaturated
fatty acid (PUFA) capsules reported beneficial effects on cardiovascular disease (CVD) …

Omega-3 polyunsaturated fatty acids (PUFAs) are a key component of a heart-healthy diet.
For patients without clinical atherosclerotic cardiovascular disease, 2 or more servings of …

The recent publication of the REDUCE-IT study has reopened the debate about the efficacy
of omega-3 fatty acids in reducing the risk of cardiovascular (CV) events. This meta-analysis …

Summary European and American Cardiac Societies incorporated EPA and DHA into recent
treatment guidelines for myocardial infarction, prevention of cardiovascular disease …

Epidemiological and clinical trial evidence suggests that ω-3 polyunsaturated fatty acids
(PUFAs) might have a significant role in the prevention of coronary heart disease. Dietary …

The most compelling evidence for the cardiovascular benefit provided by omega-3 fatty
acids comes from 3 large controlled trials of 32,000 participants randomized to receive …

We reviewed available evidence for cardiovascular effects of n-3 polyunsaturated fatty acid
(PUFA) consumption, focusing on long chain (seafood) n-3 PUFA, including their principal …

The long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA), are found in seafood, supplements, and concentrated pharmaceutical …